Detalhe da pesquisa
1.
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 22(12): 1740-1751, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34793719
2.
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Br J Cancer
; 124(2): 383-390, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33012782
3.
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer.
Int J Cancer
; 147(7): 1963-1969, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32141617
4.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Lancet Oncol
; 20(10): 1395-1408, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31422028
5.
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.
Br J Cancer
; 119(2): 153-159, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29955135
6.
Head and Neck Cancer. Reply.
N Engl J Med
; 382(20): e57, 2020 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32402180
7.
Head and Neck Cancer.
N Engl J Med
; 382(1): 60-72, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31893516
8.
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Lancet Oncol
; 18(2): 212-220, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28081914
9.
Ceritinib in ALK-rearranged non-small-cell lung cancer.
N Engl J Med
; 370(13): 1189-97, 2014 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24670165
10.
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Nature
; 477(7362): 99-102, 2011 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-21886163
11.
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Lancet Oncol
; 17(4): 452-463, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26973324
12.
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Oncologist
; 20(7): 812-22, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26069281
13.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
N Engl J Med
; 366(26): 2455-65, 2012 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22658128
14.
Neutron radiotherapy for adenoid cystic carcinoma of the lacrimal gland.
Ophthalmic Plast Reconstr Surg
; 29(4): 256-60, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23839633
15.
ACR Appropriateness Criteria® Staging and Post-Therapy Assessment of Head and Neck Cancer.
J Am Coll Radiol
; 20(11S): S521-S564, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38040469
16.
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
Cancer Med
; 12(6): 6603-6614, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36479637
17.
Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying.
Int J Pharm
; 618: 121637, 2022 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35259440
18.
Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
Target Oncol
; 17(3): 329-341, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35696014
19.
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
J Immunother Cancer
; 10(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35217573
20.
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Clin Cancer Res
; 28(12): 2506-2516, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35091443